<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="202">
  <!-- This xml conforms to:  http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>Information obtained from ClinicalTrials.gov on October 20, 2011</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01274403</url>
  </required_header>
  <id_info>
    <org_study_id>MM03</org_study_id>
    <nct_id>NCT01274403</nct_id>
  </id_info>
  <brief_title>A Randomized Study With Oral Melphalan + Prednisone (MP) Versus Melphalan, + Prednisone + Thalidomide (MPT) for Newly Diagnosesd Elderly Patients With Multiple Myeloma</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano Studio Linfomi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Italiano Studio Linfomi</source>
  <oversight_info>
    <authority>Italy: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study  is to compare efficacy and toxicity of melphalan and prednisone versus
      meplhalan, prednisone and Thalidomide in elderly patients with multiple myeloma or patients
      with multiple myeloma but not eligible for high dose treatment with stem cells support.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Masking:  Open Label</study_design>
  <primary_outcome>
    <measure>To assess the efficacy</measure>
    <time_frame>from 8 to 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To compare the percentage of response in term of  complete response, partial response, minimal and stable disease in the 2 arms o treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess the toxicity</measure>
    <time_frame>From 1 to 12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To evaluate the toxicity in the 2 arms of treatment utilized the common terminology criteria for adverse events (CTCAE) version 3.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the Overall Survival (OS) in the 2 arms of treatment</measure>
    <time_frame>From 1 to 60 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>OS was defined as the time from the date of first treatment after diagnosis of multiple myeloma to the date of last follow up examination or the date of death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the Duration of Remission (DR) in the 2 arms of treatment</measure>
    <time_frame>From 8 to 60 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>DR was defined from the date of Complete Remission, Partial Remission, Minimal response after the completion of MPT or MP cycles to the date of disease progression or the date of last follow up examination</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">130</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Melphalan, prednisone plus Thalidomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Melphalan and Prednisone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan, Prednisone and Thalidomide</intervention_name>
    <arm_group_label>Melphalan, prednisone plus Thalidomide</arm_group_label>
    <arm_group_label>Melphalan and Prednisone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  newly diagnosed of multiple myeloma.

          -  Age &gt; 65 years

          -  ECOG &lt;= 3

          -  Written informed consent given at the time of randomization

          -  Patients with age &lt;= 65 but not eligible for high dose treatment with stem cells
             support

        Exclusion Criteria:

          -  ECOG &gt; 3

          -  current neoplasm..

          -  contraindications to use thalidomide

          -  peripheral neurophaty
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Gruppo Italiano Studio Linfoma</name>
      <address>
        <city>Modena</city>
        <zip>41120</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <lastchanged_date>January 10, 2011</lastchanged_date>
  <firstreceived_date>December 28, 2010</firstreceived_date>
  <responsible_party>
    <name_title>Gruppo Italiano Studio Linfoma</name_title>
    <organization>GISL</organization>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Elderly patients</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
</clinical_study>
